CHICAGO--(BUSINESS WIRE)--CancerIQ is proud to announce that co-founder and CEO Feyi Ayodele was recognized by Modern Healthcare as one of the Innovators for 2024 expanding access to genetically informed cancer prevention, early detection and treatment. The profiles of the honorees are featured in the April 8, 2024 issue of MH magazine and online at ModernHealthcare.com/Innovator-Awards.
Modern Healthcare’s Innovators Awards & recognition program recognizes leaders and organizations thinking outside the box to improve care, achieve measurable results, and contribute to clinical and financial goals.
“The role of innovation has always been paramount in healthcare, and our 2024 honorees as top Innovators are driving real change in the industry,” said Mary Ellen Podmolik, editor in chief of Modern Healthcare. “The wide variety of projects underway by these executives and organizations demonstrates a dedication to tackling the ‘what ifs’ that can improve the delivery of healthcare and improve communities and the patient experience.”
“I’m honored to receive this incredible recognition from Modern Healthcare,” said Feyi Ayodele, CancerIQ co-founder and Chief Executive Officer. “I want to thank our team, investors, partners, and most importantly, our customers for believing in me and for propelling CancerIQ to be the best, most innovative solution in its class.”
In 2013, Feyi entered a world with niche companies offering breast cancer risk models, pedigree drawing, and telehealth genetic counseling, and pioneered solving the whole problem and not a partial one with CancerIQ's end-to-end solution. Working closely with thought leaders in the field, Feyi developed a comprehensive solution that now integrates family history, genomics, behavioral data and AI-generated risk data directly into clinical workflows. She has driven adoption of the platform across 225 diverse clinical locations and specialties to make a direct patient impact. This includes doubling the genetics workforce capacity in oncology, enhancing breast cancer risk assessment in imaging and improving overall cancer screening compliance rates — all of which benefits health systems and patients by shifting cancer diagnoses into earlier stages reducing both mortality and cost.
Unwavering in her dedication to her mission, Feyi has successfully garnered support from major players across the industry, securing over $26 million in venture capital funding led by Amgen Ventures and Merck Global Health Innovation. She has also forged partnerships with the industry’s leading diagnostic, genetic testing and pharmaceutical companies to connect everyday clinical care to the latest innovations in precision prevention, early detection and treatment.
Over the last year alone, Feyi has led CancerIQ to establish partnerships with leading AI solutions for breast cancer screening, streamline access to a marketplace of telehealth genetic counseling vendors, join the national CancerX Moonshot initiative and publish two peer-reviewed studies showing CancerIQ’s impact.
About Modern Healthcare
Modern Healthcare is the most trusted business news and information brand in the healthcare industry. Modern Healthcare empowers healthcare leaders and influencers to make timely and informed business decisions. To learn more or subscribe, go to http://www.modernhealthcare.com/subscriptions
About CancerIQ
CancerIQ is the only cancer-focused precision health platform that empowers healthcare providers to detect cancer earlier and prevent it altogether across all patient populations. Integrated directly into real-time EHR workflows, CancerIQ makes it easy to gather comprehensive patient data, automatically map it to the latest evidence-based guidelines, and expand access to personalized care plans, cutting-edge clinical solutions, and genomic innovations. Learn more at canceriq.com, follow CancerIQ on X, LinkedIn or Facebook.
